GET DAILY SIGNALSHeartFlow (HTFL): Gauging the Technical Path Toward a $65 Breakout
Key Takeaways
- The $65 objective is a fallback, publicly discussed technical level just above the 52-week high — it is not an analyst-derived consensus target.
- The average analyst price target is about $50.50, which is below the recent price near $59, meaning the stock has already outrun most Street targets.
- Moving from roughly $58–59 to $65 implies an upside of roughly 10–12%, a comparatively modest step for a high-volatility small-cap.
- The verified analyst target range spans roughly $39 to $64, with only Piper Sandler's $64 target above the current price.
- Strongest supports are accelerating revenue growth, expanding Plaque Analysis adoption, and positive clinical data; the biggest risks are persistent losses, valuation, and insider selling.
- You can track HeartFlow's Major News, Today's Price Move, Forecast, and Earnings on dedicated pages to stay current on developments that could shift the outlook.
- For automated, AI-based monitoring of this and other names, explore Trending AI Robots.
Analyst Targets and the Technical $65 Level
HeartFlow has broad but lagging analyst coverage. According to S&P Global data aggregated on stock analysis platforms, nine analysts rate the stock a consensus "Strong Buy," with an average 12-month stock price target of about $50.50 and a range from $39 to $64. Recent individual targets include Piper Sandler's $64 (Matt O'Brien, October 2026), Canaccord Genuity's $56 (William Plovanic, September 2026), UBS's $55 with a Neutral rating (September 2026), J.P. Morgan's $45, Stifel's $45, Freedom Capital Markets' $44, Morgan Stanley's $40 (Equal Weight), and Wells Fargo's $39.
Because the rounded mean of roughly $50 is below the recent share price, and because only one target ($64) sits above the price, the stock fails the standard test for a meaningful analyst-derived upside objective. The $65 figure used here is therefore a fallback target from public discussion and technical framing, not a consensus — it represents a round psychological level just above the 52-week high of $60.56 and slightly above the highest Street target. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Position and the Road to $65
Shares of HTFL recently traded around $58–59, just under a 52-week range of $20.13 to $60.56, with a market capitalization near $5.1 billion. Reaching $65 requires a gain of roughly 10–12%, a modest move in percentage terms but one that would require the stock to break decisively into record territory for the first time since its 2025 initial public offering.
The path would likely depend on continued top-line momentum rather than near-term profitability. The company remains unprofitable, so the stock's valuation is anchored to revenue growth, adoption of its FFRCT and Plaque Analysis offerings, and clinical and reimbursement milestones.
Potential Supports for Further Gains
- Accelerating revenue: trailing-twelve-month revenue near $212 million grew roughly 43% year over year, with 2025 revenue of about $176 million up roughly 40%.
- Earnings momentum: the company's Q2 2026 results beat expectations, with revenue of about $64.1 million versus a roughly $56.6 million consensus and a narrower-than-expected loss.
- Clinical validation: HeartFlow announced that its P4 study of CT-guided PCI planning met its primary endpoint, supporting the platform's clinical credibility.
- Product adoption: Plaque Analysis adoption and revenue are expanding, aided by growing payer coverage.
- AI-medtech sentiment: the stock's "Strong Buy" consensus rating reflects broad bullishness on AI-enabled diagnostics, even though most targets lag the price.
Key Risks on the Horizon
- Valuation versus fundamentals: the stock trades above almost every analyst price target for a company still posting net losses near $118 million on a trailing basis.
- Insider selling: major shareholder Bain Capital Life Sciences sold 2 million shares in a recent transaction, a signal some investors read cautiously.
- Reimbursement risk: revenue depends heavily on payer coverage and regulatory pathways for CAD diagnostics.
- Competition: the cardiac diagnostics market includes well-capitalized rivals in imaging and AI.
- Technical resistance: the $60.56 record high is a hurdle that has not yet been cleared.
Technical Levels and Market Structure
The 52-week range of $20.13 to $60.56 frames the entire move. The stock consolidated in the $48–50 area during September 2026 before rallying toward the high, making that zone a potential support level on any pullback. The $60 round number and the $60.56 record high form the key resistance level; a sustained close above that area would open the path toward the $65 objective. A failure to hold gains could test support near $50.
Time Horizon and Items to Watch
Analyst price targets generally reflect a roughly 12-month research horizon. The most immediate catalyst is the company's third-quarter 2026 earnings report, scheduled for November 12, 2026. Investors should also watch for analyst target revisions, further clinical data and regulatory updates, payer coverage decisions, and any continuation of insider selling. Because most targets already sit below the price, a disappointing quarter could prompt downward re-ratings, while sustained execution could push some analysts to lift their targets toward the current price.
Putting It All Together
HeartFlow (HTFL) has already surged roughly 190% from its 52-week low, and the shares now trade above the $50.50 average analyst price target. The $65 level is therefore best understood as a technical breakout objective — a round number just beyond the $60.56 record high and the $64 Street high — rather than a published consensus. Reaching it would require only a modest 10–12% advance, but that move hinges on continued revenue acceleration, successful product adoption, and a decisive close above record highs. Persistent losses, elevated valuation, insider selling, and resistance at the prior high are the principal obstacles. Investors should focus next on the November earnings report and any analyst target revisions.
Leveraging Tickeron’s AI Daily Buy/Sell Signals
In my own workflow, I turn to Tickeron’s AI Daily Buy/Sell Signals to monitor fast-moving names like this one. The tool applies AI to thousands of stocks and ETFs, surfacing Buy, Sell, or Hold signals based on technical shifts and market conditions. It helps me stay efficient when tracking high-volatility opportunities without replacing my own research.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for HTFL turns positive, indicating new upward trend
HTFL saw its Momentum Indicator move above the 0 level on October 20, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator turned positive. In 23 of the 25 cases, the stock moved higher in the following days. The odds of a move higher are at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for HTFL just turned positive on October 20, 2026. Looking at past instances where HTFL's MACD turned positive, the stock continued to rise in 9 of 9 cases over the following month. The odds of a continued upward trend are 90%.
Following a +4.69% 3-day Advance, the price is estimated to grow further. Considering data from situations where HTFL advanced for three days, in 77 of 85 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
The Aroon Indicator entered an Uptrend today. In 51 of 59 cases where HTFL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 86%.
Bearish Trend Analysis
The 10-day RSI Indicator for HTFL moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 6 similar instances where the indicator moved out of overbought territory. In 6 of the 6 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HTFL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
HTFL broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 26 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (18.356) is normal, around the industry mean (4.705). P/E Ratio (-18.718) is within average values for comparable stocks, (13.222). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.133). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. HTFL's P/S Ratio (19.763) is slightly higher than the industry average of (6.065).
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. HTFL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HTFL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 97, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry ServicestotheHealthIndustry
Advertisement